{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-036496","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2021-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.671233+00:00","generated_at":"2026-06-30T05:29:14.327756+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Nkarta signs 12-year lease for 88,106 sq ft manufacturing and HQ facility in South San Francisco","bullets":["Monthly base rent starts at ~$564K, escalating to ~$823K; tenant improvement allowance up to $25.2M.","Facility will support research, development, and commercial manufacturing of NK cell therapy pipeline.","Expected operational by end of 2023; planned production for pivotal trials and commercial launch.","Nkarta retains existing 2,700 sq ft cGMP facility for early-stage clinical manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-036496","json":"https://secwatch.observer/filing/0001564590-21-036496.json","markdown":"https://secwatch.observer/filing/0001564590-21-036496.md","text":"https://secwatch.observer/filing/0001564590-21-036496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/0001564590-21-036496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/nktx-8k_20210709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T05:29:14.327756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}